KEDP
Evidence Grade E — Very limited evidence. 5 published studies. 0 registered clinical trials.
Prostamax is a synthetic tetrapeptide from the Khavinson bioregulator programme, proposed to target prostate tissue. No human clinical trials have been conducted. An animal study (60 rats) in a prostate inflammation model has been reported. It has no regulatory approval.
5 published studies: 4 human, 1 animal, 0 in-vitro, 0 reviews
Prostamax has no marketing authorisation from any major regulatory agency. No human clinical trials have been conducted. An animal study (60 rats) comparing Prostamax against existing prostate treatments in a chronic prostatitis model has been reported, but this is a single preclinical study.
As with other Khavinson bioregulator peptides, the proposed tissue-specific targeting mechanisms have not been independently validated. Products available through unregulated channels lack pharmaceutical quality assurance.
Research from the Khavinson group proposes that Prostamax may promote chromatin decondensation in prostate tissue through epigenetic regulation. Molecular modelling suggests potential interactions with amino acid transporters. These proposed mechanisms are computational predictions and have not been experimentally confirmed in human tissue.
Only 2-3 peer-reviewed studies directly on Prostamax exist. The primary animal study was published in a minor journal with no blinding described. No human clinical trials, no pharmacokinetic data, no dose-response studies, and no independent replication exist. Computational modelling suggests potential molecular interactions but these predictions have not been experimentally confirmed. Products from unregulated channels lack pharmaceutical quality assurance.
No trials registered on ClinicalTrials.gov for this compound.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Histrelin is available as Supprelin LA for central precocious puberty (approved 2007). The Vantas implant for prostate cancer was approved in 2004 but discontinued in 2021. The implant requires a minor surgical procedure for insertion and removal/replacement each year. Supprelin LA's main clinical advantage is its 12-month duration — the longest of any GnRH agonist — which is particularly valuable in paediatric patients where treatment compliance over years is important. Clinical studies demonstrated effective suppression of puberty markers in over 97% of patients. The implant has also seen significant off-label use in gender-affirming care as a puberty blocker, where its annual dosing schedule offers practical benefits for adolescent patients and their families.
Goserelin is marketed as Zoladex by AstraZeneca, available as 3.6 mg monthly and 10.8 mg three-monthly subcutaneous implants. First approved in 1989, it is used in advanced prostate cancer, premenopausal breast cancer, endometriosis, and for thinning the uterine lining before surgical procedures. Goserelin achieves castrate-level testosterone suppression (below 50 ng/dL) within two to four weeks. Its unique implant delivery system means there is no liquid injection, reconstitution, or refrigeration required — a practical advantage in some clinical settings. Like all GnRH agonists, it causes an initial hormone flare before suppression takes effect. Goserelin holds an important niche in breast cancer treatment, where it is used to suppress ovarian function in premenopausal women with hormone-receptor-positive disease, often in combination with aromatase inhibitors.
Nafarelin is marketed as Synarel (approved 1990) for endometriosis and central precocious puberty. It requires administration as one spray in each nostril twice daily — a higher frequency than injectable alternatives but avoids needles entirely, which can be a significant advantage for some patients, particularly children. Clinical trials showed symptom improvement in 75–92% of endometriosis patients. However, absorption can be affected by nasal congestion or concurrent use of nasal decongestants, which can be a practical limitation. As with all GnRH agonists, prolonged use leads to bone density loss, and treatment for endometriosis is typically limited to six months. Nafarelin occupies a niche for patients who prefer non-injectable hormone suppression, though it has become less commonly prescribed as longer-acting depot injections and oral alternatives have become available.
